Phase II study of combination human recombinant GM-CSF with intermediate-dose cytarabine and mitoxantrone chemotherapy in patients with high-risk myelodysplastic syndromes (RAEB, RAEBT, and CMML): An eastern cooperative oncology group study

John M. Bennett, Mary S. Young, Jane L. Liesveld, Elisabeth M. Paietta, Kenneth B. Miller, Hillard M. Lazarus, Robert D. Marsh, William R. Friedenberg, Hussain T. Saba, F. Ann Hayes, Gordon W. Dewald, Wolfgang Hiddemann, Jacob M. Rowe

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

A Phase II study of GM-CSF with intermediate-dose cytarabine and mitoxantrone was conducted in patients with high-risk myelodysplastic syndrome. It was designed to evaluate if priming with growth factor could increase the efficiency of chemotherapy. In this older population only two of 10 patients achieved a bone marrow CR, including one patient whose leukemic blasts had an 'S' phase increase of 2.55x at 48 hr. Unexpected hepatotoxicity was noted. This regimen cannot be recommended for this elderly population of patients. (C) 2001 Wiley-Liss, Inc.

Original languageEnglish (US)
Pages (from-to)23-27
Number of pages5
JournalAmerican Journal of Hematology
Volume66
Issue number1
DOIs
StatePublished - 2001
Externally publishedYes

Fingerprint

Refractory Anemia with Excess of Blasts
Mitoxantrone
Myelodysplastic Syndromes
Cytarabine
Granulocyte-Macrophage Colony-Stimulating Factor
Drug Therapy
S Phase
Population
Intercellular Signaling Peptides and Proteins
Bone Marrow

Keywords

  • Cytarabine
  • GM-CSF
  • Mitoxantrone
  • Myelodysplastic syndromes

ASJC Scopus subject areas

  • Hematology

Cite this

Phase II study of combination human recombinant GM-CSF with intermediate-dose cytarabine and mitoxantrone chemotherapy in patients with high-risk myelodysplastic syndromes (RAEB, RAEBT, and CMML) : An eastern cooperative oncology group study. / Bennett, John M.; Young, Mary S.; Liesveld, Jane L.; Paietta, Elisabeth M.; Miller, Kenneth B.; Lazarus, Hillard M.; Marsh, Robert D.; Friedenberg, William R.; Saba, Hussain T.; Ann Hayes, F.; Dewald, Gordon W.; Hiddemann, Wolfgang; Rowe, Jacob M.

In: American Journal of Hematology, Vol. 66, No. 1, 2001, p. 23-27.

Research output: Contribution to journalArticle

Bennett, John M. ; Young, Mary S. ; Liesveld, Jane L. ; Paietta, Elisabeth M. ; Miller, Kenneth B. ; Lazarus, Hillard M. ; Marsh, Robert D. ; Friedenberg, William R. ; Saba, Hussain T. ; Ann Hayes, F. ; Dewald, Gordon W. ; Hiddemann, Wolfgang ; Rowe, Jacob M. / Phase II study of combination human recombinant GM-CSF with intermediate-dose cytarabine and mitoxantrone chemotherapy in patients with high-risk myelodysplastic syndromes (RAEB, RAEBT, and CMML) : An eastern cooperative oncology group study. In: American Journal of Hematology. 2001 ; Vol. 66, No. 1. pp. 23-27.
@article{8a6fce8bfe0d43c9b0abde299120f701,
title = "Phase II study of combination human recombinant GM-CSF with intermediate-dose cytarabine and mitoxantrone chemotherapy in patients with high-risk myelodysplastic syndromes (RAEB, RAEBT, and CMML): An eastern cooperative oncology group study",
abstract = "A Phase II study of GM-CSF with intermediate-dose cytarabine and mitoxantrone was conducted in patients with high-risk myelodysplastic syndrome. It was designed to evaluate if priming with growth factor could increase the efficiency of chemotherapy. In this older population only two of 10 patients achieved a bone marrow CR, including one patient whose leukemic blasts had an 'S' phase increase of 2.55x at 48 hr. Unexpected hepatotoxicity was noted. This regimen cannot be recommended for this elderly population of patients. (C) 2001 Wiley-Liss, Inc.",
keywords = "Cytarabine, GM-CSF, Mitoxantrone, Myelodysplastic syndromes",
author = "Bennett, {John M.} and Young, {Mary S.} and Liesveld, {Jane L.} and Paietta, {Elisabeth M.} and Miller, {Kenneth B.} and Lazarus, {Hillard M.} and Marsh, {Robert D.} and Friedenberg, {William R.} and Saba, {Hussain T.} and {Ann Hayes}, F. and Dewald, {Gordon W.} and Wolfgang Hiddemann and Rowe, {Jacob M.}",
year = "2001",
doi = "10.1002/1096-8652(200101)66:1<23::AID-AJH1002>3.0.CO;2-B",
language = "English (US)",
volume = "66",
pages = "23--27",
journal = "American Journal of Hematology",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",
number = "1",

}

TY - JOUR

T1 - Phase II study of combination human recombinant GM-CSF with intermediate-dose cytarabine and mitoxantrone chemotherapy in patients with high-risk myelodysplastic syndromes (RAEB, RAEBT, and CMML)

T2 - An eastern cooperative oncology group study

AU - Bennett, John M.

AU - Young, Mary S.

AU - Liesveld, Jane L.

AU - Paietta, Elisabeth M.

AU - Miller, Kenneth B.

AU - Lazarus, Hillard M.

AU - Marsh, Robert D.

AU - Friedenberg, William R.

AU - Saba, Hussain T.

AU - Ann Hayes, F.

AU - Dewald, Gordon W.

AU - Hiddemann, Wolfgang

AU - Rowe, Jacob M.

PY - 2001

Y1 - 2001

N2 - A Phase II study of GM-CSF with intermediate-dose cytarabine and mitoxantrone was conducted in patients with high-risk myelodysplastic syndrome. It was designed to evaluate if priming with growth factor could increase the efficiency of chemotherapy. In this older population only two of 10 patients achieved a bone marrow CR, including one patient whose leukemic blasts had an 'S' phase increase of 2.55x at 48 hr. Unexpected hepatotoxicity was noted. This regimen cannot be recommended for this elderly population of patients. (C) 2001 Wiley-Liss, Inc.

AB - A Phase II study of GM-CSF with intermediate-dose cytarabine and mitoxantrone was conducted in patients with high-risk myelodysplastic syndrome. It was designed to evaluate if priming with growth factor could increase the efficiency of chemotherapy. In this older population only two of 10 patients achieved a bone marrow CR, including one patient whose leukemic blasts had an 'S' phase increase of 2.55x at 48 hr. Unexpected hepatotoxicity was noted. This regimen cannot be recommended for this elderly population of patients. (C) 2001 Wiley-Liss, Inc.

KW - Cytarabine

KW - GM-CSF

KW - Mitoxantrone

KW - Myelodysplastic syndromes

UR - http://www.scopus.com/inward/record.url?scp=0035191168&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035191168&partnerID=8YFLogxK

U2 - 10.1002/1096-8652(200101)66:1<23::AID-AJH1002>3.0.CO;2-B

DO - 10.1002/1096-8652(200101)66:1<23::AID-AJH1002>3.0.CO;2-B

M3 - Article

C2 - 11426487

AN - SCOPUS:0035191168

VL - 66

SP - 23

EP - 27

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

IS - 1

ER -